Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Launched by HOSPITAL REGIONAL DE ALTA ESPECIALIDAD DEL BAJIO · Oct 24, 2022

Keywords

ClinConnect Summary

This clinical trial is researching a new treatment approach for adults with relapsed or refractory Hodgkin lymphoma, which means their cancer has returned or has not responded to previous treatments. The study will specifically look at how effective a combination of two therapies—Brentuximab (a targeted therapy) and PD-1 blockade (an immunotherapy)—is when used together with a procedure called autologous hematopoietic stem cell transplantation (auto-HSCT). Researchers want to find out how long patients can stay free from cancer (progression-free survival) and how many achieve a complete metabolic response, meaning their cancer is no longer detectable.

To participate in this trial, participants need to be between 18 and 90 years old and have been diagnosed with high-risk relapsed or refractory Hodgkin lymphoma after receiving a standard treatment called ABVD. They must also have good liver and kidney function. Participants will undergo the treatment and will be monitored closely throughout the study. This trial is currently recruiting participants, and it aims to provide valuable insights into better treatment options for those facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
• • 2. Age ≥ 18 years and ≤ 90 years.
• 3. Adequate liver function, defined as:
• • Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
• • Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
• • Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN
• 4. Adequate renal functions, defined as:
• • • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \> 50ml/min.
• • 5. ECOG performance status ≤ 3
• • 6. Women of reproductive potential should have a serum pregnancy test or negative urine.
• • 7. Prior signature of the informed consent.
• Exclusion Criteria:
• • 1. Voluntary withdrawal from the study.
• • 2. Develop grade 3 or 4 toxicity according to the INH scale.
• • 3. Loss of follow-up